Petros Stellatos
Petros Stellatos has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros Gryparis
Department of Speech and Language Therapy, University of Ioannina, 45500 Ioannina, Greece
2 shared publications - Anastasia Evangelia Konstantinidou
Unit of Pediatric-Perinatal Pathology, First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2 shared publications - Anastassios Philippou
Department of Physiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2 shared publications - Fani-Niki Varra
Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus
2 shared publications - Kleopatra Paparizou
Unit of Pediatric-Perinatal Pathology, First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2 shared publications - Michail Varras
Fourth Department of Obstetrics and Gynecology, ‘Elena Venizelou’ General and Maternity Hospital, 11521 Athens, Greece
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1281
IGF-1Eb Isoform Immunoreactivity May Be Associated with Placental Dysfunction and Vascular Pathology in Fetal Growth Restriction (FGR)
Background: Fetal growth restriction (FGR) is associated with placental dysfunction and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is important for placental and fetal development, the mRNA expression, immunopositivity and potential biological significance of specific IGF-1 isoforms in FGR remain incompletely characterized. This study investigated placental IGF-1Eb mRNA expression and immunopositivity in FGR pregnancies compared with appropriate-for-gestational-age (AGA) pregnancies. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by FGR and 15 from pregnancies with AGA fetal growth. The mRNA expression of the IGF-1Eb isoform was assessed by reverse-transcription quantitative PCR in a subset of 28 fresh placental samples. IGF-1Eb protein immunoreactivity was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and associations with clinical, demographic, and pathological parameters were evaluated using appropriate statistical analyses. Results: IGF-1Eb mRNA expression did not differ significantly between the FGR and AGA groups. In contrast, significant differences in IGF-1Eb immunoreactivity were observed in selected placental compartments. Moderate immunoreactivity in the perivillous syncytiotrophoblast was more frequent in FGR placentas and was associated with histological features of maternal vascular malperfusion, as well as with gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Increased IGF-1Eb immunopositivity was also observed in the endothelium of maternal decidual and fetal villous vessels in FGR placentas. No significant differences were observed in IGF-1Eb immunoreactivity in the extravillous trophoblast. Conclusions: In this observational study, placental IGF-1Eb protein immunoreactivity, but not mRNA expression, differed between FGR and AGA pregnancies in selected placental compartments. These findings indicate compartment-specific differences in IGF-1Eb protein immunoreactivity, associated with FGR and placental pathological features. However, the observational and cross-sectional design does not establish causality or a functional role for IGF-1Eb in placental dysfunction. Larger prospective studies incorporating functional validation are required to clarify the biological significance of these findings.
- 4 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1281
Open AccessIGF-1Eb Isoform Immunoreactivity May Be Associated with Placental Dysfunction and Vascular Pathology in Fetal Growth Restriction (FGR)
Background: Fetal growth restriction (FGR) is associated with placental dysfunction and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is important for placental and fetal development, the mRNA expression, immunopositivity and potential biological significance of specific IGF-1 isoforms in FGR remain incompletely characterized. This study investigated placental IGF-1Eb mRNA expression and immunopositivity in FGR pregnancies compared with appropriate-for-gestational-age (AGA) pregnancies. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by FGR and 15 from pregnancies with AGA fetal growth. The mRNA expression of the IGF-1Eb isoform was assessed by reverse-transcription quantitative PCR in a subset of 28 fresh placental samples. IGF-1Eb protein immunoreactivity was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and associations with clinical, demographic, and pathological parameters were evaluated using appropriate statistical analyses. Results: IGF-1Eb mRNA expression did not differ significantly between the FGR and AGA groups. In contrast, significant differences in IGF-1Eb immunoreactivity were observed in selected placental compartments. Moderate immunoreactivity in the perivillous syncytiotrophoblast was more frequent in FGR placentas and was associated with histological features of maternal vascular malperfusion, as well as with gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Increased IGF-1Eb immunopositivity was also observed in the endothelium of maternal decidual and fetal villous vessels in FGR placentas. No significant differences were observed in IGF-1Eb immunoreactivity in the extravillous trophoblast. Conclusions: In this observational study, placental IGF-1Eb protein immunoreactivity, but not mRNA expression, differed between FGR and AGA pregnancies in selected placental compartments. These findings indicate compartment-specific differences in IGF-1Eb protein immunoreactivity, associated with FGR and placental pathological features. However, the observational and cross-sectional design does not establish causality or a functional role for IGF-1Eb in placental dysfunction. Larger prospective studies incorporating functional validation are required to clarify the biological significance of these findings.
- Open Access
- 1 July 2026
- Published by MDPI AG in Preprints.org
IGF-1Eb Isoform May Be Associated with Placental Dysfunction and Vascular Pathology in Idiopathic Intrauterine Growth Restriction (IUGR)
Background: Idiopathic intrauterine growth restriction (IUGR) is strongly associated with placental dysfunction, impaired spiral uterine artery remodeling, and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is essential for placental and fetal development, the role of specific IGF-1 isoforms remains unclear. This study investigated placental IGF-1Eb expression in idiopathic IUGR and its potential as a biomarker of placental dysfunction. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by idiopathic intrauterine growth restriction (IUGR) and 15 from pregnancies with appropriate-for-gestational-age (AGA) fetal growth, which served as the control group. The mRNA expression levels of the IGF-1Eb isoform were assessed by reverse transcription quantitative PCR in a subset of 28 fresh placental samples. The immunoexpression of IGF-1Eb protein was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and correlations with clinical, demographic and pathological parameters were assessed using appropriate statistical analyses. Results: The mRNA expression of the IGF-1Eb isoform in placentas did not differ significantly between the IUGR and AGA groups. In contrast, immunohistochemical analysis revealed statistically significant differences in IGF-1Eb protein expression. The protein localization was cytoplasmic, perimembranous and occasionally nuclear, expressed in the perivillous and extravillous trophoblast, and the endothelium of fetal and maternal vessels. Moderate IGF-1Eb immunoexpression in the perivillous syncytiotrophoblast was observed significantly more frequently in IUGR placentas compared with the AGA group and was associated with histological changes of maternal vascular malperfusion, and with clinical parameters, including gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Furthermore, a significant increase in IGF-1Eb immunopositivity was observed in the endothelium of maternal decidual and fetal villous vessels in IUGR placentas. In contrast, no statistically significant differences were recorded in the scores or intensity of IGF-1Eb immunoexpression in the extravillous trophoblast between the two groups. Conclusions: Although total IGF-1Eb mRNA levels remained unchanged, increased protein immunoexpression was associated with idiopathic IUGR in distinct parts of the placenta. In association with histological changes of maternal vascular malperfusion, these findings suggest that IGF-1Eb may serve as a potential marker of placental dysfunction in IUGR pregnancies.
- 1 July 2026
- Published by MDPI AG in Preprints.org
Open AccessIGF-1Eb Isoform May Be Associated with Placental Dysfunction and Vascular Pathology in Idiopathic Intrauterine Growth Restriction (IUGR)
Background: Idiopathic intrauterine growth restriction (IUGR) is strongly associated with placental dysfunction, impaired spiral uterine artery remodeling, and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is essential for placental and fetal development, the role of specific IGF-1 isoforms remains unclear. This study investigated placental IGF-1Eb expression in idiopathic IUGR and its potential as a biomarker of placental dysfunction. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by idiopathic intrauterine growth restriction (IUGR) and 15 from pregnancies with appropriate-for-gestational-age (AGA) fetal growth, which served as the control group. The mRNA expression levels of the IGF-1Eb isoform were assessed by reverse transcription quantitative PCR in a subset of 28 fresh placental samples. The immunoexpression of IGF-1Eb protein was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and correlations with clinical, demographic and pathological parameters were assessed using appropriate statistical analyses. Results: The mRNA expression of the IGF-1Eb isoform in placentas did not differ significantly between the IUGR and AGA groups. In contrast, immunohistochemical analysis revealed statistically significant differences in IGF-1Eb protein expression. The protein localization was cytoplasmic, perimembranous and occasionally nuclear, expressed in the perivillous and extravillous trophoblast, and the endothelium of fetal and maternal vessels. Moderate IGF-1Eb immunoexpression in the perivillous syncytiotrophoblast was observed significantly more frequently in IUGR placentas compared with the AGA group and was associated with histological changes of maternal vascular malperfusion, and with clinical parameters, including gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Furthermore, a significant increase in IGF-1Eb immunopositivity was observed in the endothelium of maternal decidual and fetal villous vessels in IUGR placentas. In contrast, no statistically significant differences were recorded in the scores or intensity of IGF-1Eb immunoexpression in the extravillous trophoblast between the two groups. Conclusions: Although total IGF-1Eb mRNA levels remained unchanged, increased protein immunoexpression was associated with idiopathic IUGR in distinct parts of the placenta. In association with histological changes of maternal vascular malperfusion, these findings suggest that IGF-1Eb may serve as a potential marker of placental dysfunction in IUGR pregnancies.